Involvement of angiotensin II in intestinal cholesterol absorption

Pharmacological Research

Volumn 61, Issue 5, 2010, Pages 460-465

  Nakamura, Kazuo ^a   Matsui, Takanori ^b   Adachi, Hisashi ^b   Yamagishi, Sho Ichi ^b  

^a Nakamura Clinic   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Cholesterol absorption; NPC1L1; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALKALINE PHOSPHATASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CELL PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NIEMANN PICK C1 LIKE 1 PROTEIN; RENIN INHIBITOR; SITOSTEROL; UNCLASSIFIED DRUG;

AGED; ANAMNESIS; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG USE; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTESTINE ABSORPTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AGED; ALKALINE PHOSPHATASE; ANGIOTENSIN II; ANTILIPEMIC AGENTS; BLOTTING, WESTERN; CACO-2 CELLS; CHOLESTEROL; FEMALE; GENE EXPRESSION; HUMANS; INTESTINAL ABSORPTION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SITOSTEROLS;

EID: 77950628016     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.12.002     Document Type: Article

References (37)

1. Zhao H.L., Houweling A.H., Vanstone C.A., Jew S., Trautwein E.A., Duchateau G.S., et al. Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men. Lipids 2008, 43:1155-1164.
2. Tang W., Ma Y., Jia L., Ioannou Y.A., Davies J.P., Yu L. Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5/ABCG8. J Lipid Res 2009, 50:293-300.
3. Kidambi S., Patel S.B. Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. Xenobiotica 2008, 38:1119-1139.
4. Hui D.Y., Labonté E.D., Howles P.N. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption. Am J Physiol Gastrointest Liver Physiol 2008, 294:G839-G843.
5. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tezloff G., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
6. Davis H.R., Altmann S.W. Niemann-Pick C1 like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta 2009, 1791:679-683.
7. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Ueda Y., Suzuki T., et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmcol Res 2009, 60:525-528.
8. Filippatos T.D., Mikhailidis D.P. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009, 15:490-516.
9. Sudhop T., Lütjohann D., Kodal A., Igel M., Tribble D.L., Shah S., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 122:829-839.
10. Matthan N.R., Pencina M., Larocque J.M., Jacques P.F., D'Agostino R.B., Schaefer E.J., et al. Alterations in cholesterol absorption and synthesis characterize Framingham offspring study participants with coronary heart disease. J Lipid Res 2009, 50:1927-1935.
11. Assmann G., Cullen P., Erbey J., Ramey D.R., Kannenberg F., Schulte H. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study. Nutr Metab Cardiovasc Dis 2006, 16:13-21.
12. Escurriol V, Cofan M, Moreno-Iribas C, Larranaga N, Martinez C, Navarro C, et al. Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort. J Lipid Res; in press.
13. Windler E., Zyriax B.C., Kuipers F., Linseisen J., Boeing H. Association of plasma phytosterol concentrations with incident coronary heart disease Data from the CORA study, a case-control study of coronary artery disease in women. Atherosclerosis 2009, 203:284-290.
14. Fassbender K., Lütjohann D., Dik M.G., Bremmer M., König J., Walter S., et al. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk-the LASA study. Atherosclerosis 2008, 196:283-288.
15. Pinedo S., Vissers M.N., von Bergmann K., Elharchaoui K., Lütjohann D., Luben R., et al. Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. J Lipid Res 2007, 48:139-144.
16. Wilund K.R., Yu L., Xu F., Vega G.L., Grundy S.M., Cohen J.C., et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol 2004, 24:2326-2332.
17. Watts G.F., Chan D.C., Barrett P.H., O'Neill F.H., Thompson G.R. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 2003, 27:862-865.
18. Valasek M.A., Clarke S.L., Repa J.J. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 2007, 48:2725-2735.
19. Lally S., Owens D., Tomkin G.H. The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes. Atherosclerosis 2007, 193:343-351.
20. Guzmán-Aránguez A., Olmo N., Turnay J., Lecona E., Pérez-Ramos P., López de Silanes I., et al. Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5. J Cell Biochem 2005, 94:178-193.
21. Yamashita S., Konishi K., Yamazaki Y., Taki Y., Sakane T., Sezaki H., et al. New and better protocols for a short-term Caco-2 cell culture system. J Pharm Sci 2002, 91:669-679.
22. Nakano T., Inoue I., Katayama S., Seo M., Takahashi S., Hokari S., et al. Lysophosphatidylcholine for efficient intestinal lipid absorption and lipoprotein secretion in caco-2 cells. J Clin Biochem Nutr 2009, 45:227-234.
23. Pinto M., Robine-Leon S., Appay M.D., Kerdinger M., Triadou N., Dussaulx E., et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 1983, 47:323-330.
24. Matsumoto H., Erickson R.H., Gum J.R., Yoshioka M., Gum E., Kim Y.S. Biosynthesis of alkaline phosphatase during differentiation of the human colon cancer cell line Caco-2. Gastroenterology 1990, 98:1199-1207.
25. Imai E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007, 11:41-50.
26. Marino M.R., Langenbacher K., Ford N.F., Uderman H.D. J Clin Pharmacol 1998, 138:246-255.
27. Yamagishi S., Takeuchi M., Matsui T., Nakamura K., Imaizumi T., Inoue H. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005, 579:4265-4270.
28. Kesäniemi Y.A., Miettinen T.A. Cholesterol absorption efficiently regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987, 17:391-395.
29. Peltola P., Pihlajamäki J., Koutnikova H., Ruotsalainen E., Salmenniemi U., Vauhkonen I., et al. Visceral obesity is associated with high levels of serum squalene. Obesity (Silver Spring) 2006, 14:1155-1163.
30. Stranberg T.E., Salomaa V., Vanhanen H., Miettinen T.A. Associations of fasting blood glucose with cholesterol absorption and synthesis in nondiabetic middle-aged men. Diabetes 1996, 45:755-761.
31. Yamagishi S., Matsui T., Nakamura K., Imaizumi T. Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Protein Pept Lett 2007, 14:615-617.
32. Yamagishi S., Nakamura K., Ueda S., Kato S., Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res 2005, 320:437-445.
33. Ravid Z., Bendayan M., Delvin E., Sane A.T., Elchebly M., Lafond J., et al. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol 2008, 295:G873-G885.
34. Lally S., Tan C.Y., Owens D., Tomkin G.H. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006, 49:1008-1016.
35. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11:2279-2299.
36. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008, 17:983-996.
37. Yamagishi S., Matsui T., Takenaka K., Nakamura K., Takeuchi M., Inoue H. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009, 25:266-271.